Literature DB >> 16804313

Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient.

Don S Dizon1, Trevor Tejada-Berges, Susan Koelliker, Margaret Steinhoff, Cornelius O Granai.   

Abstract

Ovarian cancer is the most fatal gynecologic malignancy. Women often present late and though median survival has improved, a majority of women will succumb to their disease. The incidence of ovarian cancer among female-to-male transsexuals is not known. We report only the second case of ovarian cancer in a female-to-male transsexual while on androgen supplementation therapy. Staining of his tumor for androgen receptors showed abundant expression. Androgen supplementation in this population may be associated with an increased risk of both ovarian cancer and of endometrial cancer. Consideration for bilateral salpingo-oophorectomy as part of gender reassignment surgery should be given, especially in this poorly studied group of patients whose overall risk of ovarian cancer remains unknown. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16804313     DOI: 10.1159/000094097

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  10 in total

Review 1.  Challenges in Transgender Healthcare: The Pathology Perspective.

Authors:  Sarika Gupta; Katherine L Imborek; Matthew D Krasowski
Journal:  Lab Med       Date:  2016-06-10

Review 2.  Cancer in Transgender People: Evidence and Methodological Considerations.

Authors:  Hayley Braun; Rebecca Nash; Vin Tangpricha; Janice Brockman; Kevin Ward; Michael Goodman
Journal:  Epidemiol Rev       Date:  2017-01-01       Impact factor: 6.222

3.  Standards of Care for the Health of Transgender and Gender Diverse People, Version 8.

Authors:  E Coleman; A E Radix; W P Bouman; G R Brown; A L C de Vries; M B Deutsch; R Ettner; L Fraser; M Goodman; J Green; A B Hancock; T W Johnson; D H Karasic; G A Knudson; S F Leibowitz; H F L Meyer-Bahlburg; S J Monstrey; J Motmans; L Nahata; T O Nieder; S L Reisner; C Richards; L S Schechter; V Tangpricha; A C Tishelman; M A A Van Trotsenburg; S Winter; K Ducheny; N J Adams; T M Adrián; L R Allen; D Azul; H Bagga; K Başar; D S Bathory; J J Belinky; D R Berg; J U Berli; R O Bluebond-Langner; M-B Bouman; M L Bowers; P J Brassard; J Byrne; L Capitán; C J Cargill; J M Carswell; S C Chang; G Chelvakumar; T Corneil; K B Dalke; G De Cuypere; E de Vries; M Den Heijer; A H Devor; C Dhejne; A D'Marco; E K Edmiston; L Edwards-Leeper; R Ehrbar; D Ehrensaft; J Eisfeld; E Elaut; L Erickson-Schroth; J L Feldman; A D Fisher; M M Garcia; L Gijs; S E Green; B P Hall; T L D Hardy; M S Irwig; L A Jacobs; A C Janssen; K Johnson; D T Klink; B P C Kreukels; L E Kuper; E J Kvach; M A Malouf; R Massey; T Mazur; C McLachlan; S D Morrison; S W Mosser; P M Neira; U Nygren; J M Oates; J Obedin-Maliver; G Pagkalos; J Patton; N Phanuphak; K Rachlin; T Reed; G N Rider; J Ristori; S Robbins-Cherry; S A Roberts; K A Rodriguez-Wallberg; S M Rosenthal; K Sabir; J D Safer; A I Scheim; L J Seal; T J Sehoole; K Spencer; C St Amand; T D Steensma; J F Strang; G B Taylor; K Tilleman; G G T'Sjoen; L N Vala; N M Van Mello; J F Veale; J A Vencill; B Vincent; L M Wesp; M A West; J Arcelus
Journal:  Int J Transgend Health       Date:  2022-09-06

4.  Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression.

Authors:  Miriam S Butler; Carmela Ricciardelli; Wayne D Tilley; Theresa E Hickey
Journal:  Horm Cancer       Date:  2013-02-27       Impact factor: 3.869

5.  Androgen receptor increases CD133 expression and progenitor-like population that associate with cisplatin resistance in endometrial cancer cell line.

Authors:  Lumin Chen; Wei-Chun Chang; Yao-Ching Hung; Ying-Yi Chang; Bo-Yin Bao; Hsin-Ching Huang; Wei-Min Chung; Chih-Rong Shyr; Wen-Lung Ma
Journal:  Reprod Sci       Date:  2013-08-20       Impact factor: 3.060

6.  Cancer's Margins: Trans* and Gender Nonconforming People's Access to Knowledge, Experiences of Cancer Health, and Decision-Making.

Authors:  Evan T Taylor; Mary K Bryson
Journal:  LGBT Health       Date:  2015-11-13       Impact factor: 4.151

Review 7.  The Role of Androgen Receptor Signaling in Ovarian Cancer.

Authors:  Taichi Mizushima; Hiroshi Miyamoto
Journal:  Cells       Date:  2019-02-19       Impact factor: 6.600

8.  Fallopian Tube-Derived Tumor Cells Induce Testosterone Secretion from the Ovary, Increasing Epithelial Proliferation and Invasion.

Authors:  Jose A Colina; Katherine E Zink; Kanella Eliadis; Reza Salehi; Emma S Gargus; Sarah R Wagner; Kristine J Moss; Seth Baligod; Kailiang Li; Brenna J Kirkpatrick; Teresa K Woodruff; Benjamin K Tsang; Laura M Sanchez; Joanna E Burdette
Journal:  Cancers (Basel)       Date:  2021-04-16       Impact factor: 6.639

9.  Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study.

Authors:  Britton Trabert; Kara A Michels; Garnet L Anderson; Louise A Brinton; Roni T Falk; Ashley M Geczik; Holly R Harris; Kathy Pan; Ruth M Pfeiffer; Lihong Qi; Thomas Rohan; Nicolas Wentzensen; Xia Xu
Journal:  Int J Cancer       Date:  2019-02-15       Impact factor: 7.316

Review 10.  Gynaecological aspects of the treatment and follow-up of transsexual men and women.

Authors:  S Weyers; P De Sutter; S Hoebeke; G Monstrey; G 'T Sjoen; H Verstraelen; J Gerris
Journal:  Facts Views Vis Obgyn       Date:  2010
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.